Skip to main content

Table 3 Details of immune-related adverse events (AEs) in the study cohort

From: Association between pretreatment lymphocyte count and response to PD1 inhibitors in head and neck squamous cell carcinomas

Immune-related AEs

Any grade

(# of patients)

Any grade

(% of patients)

Grade 3 or 4

(# of patients)

Grade 3 or 4

(% of patients)

All types

8a

23.5%a

3

8.8%

Dermatitis – Rash

1

2.9%

0

0

Colitis

2

5.9%

0

0

Thyroiditis

3

8.8%

0

0

Pneumonitis

3

8.8%

2

5.9%

Thrombocytopenia

1

2.9%

0

0

Others

 Autonomic dysregulation

1

2.9%

1

2.9%

 Renal graft rejection

1

2.9%

N/A

N/A

  1. aSome patients developed more than one type of immune-related AEs